ABSTRACT
The relationship of SARS-CoV-2 lung infection and severity of pulmonary disease is not fully understood. We analyzed autopsy specimens from 24 patients who succumbed to SARS-CoV-2 infection using a combination of different RNA and protein analytical platforms to characterize inter- and intra-patient heterogeneity of pulmonary virus infection. There was a spectrum of high and low virus cases that was associated with duration of disease and activation of interferon pathway genes. Using a digital spatial profiling platform, the virus corresponded to distinct spatial expression of interferon response genes and immune checkpoint genes demonstrating the intra-pulmonary heterogeneity of SARS-CoV-2 infection.
Competing Interest Statement
David Ting has received consulting fees from Merrimack Pharmaceuticals Ventana Roche Foundation Medicine Inc and EMD Millipore Sigma which are not related to this work. David Ting is a founder and has equity in PanTher Therapeutics and TellBio Inc which is not related to this work. David Ting and BDG are co-founders and own equity in ROME Therapeutics which is not related to this work. Parts of this work were supported by ACD-Biotechne (ND, AN, ASK, VD, MNR, DTT) Interests of David Ting were reviewed and are managed by Mass General Brigham in accordance with their conflict of interest policies. Robert Monroe is an employee of ACD Biotechne. Sarah E Warren, Patrick Danaher, Jason W. Reeves, Jingjing Gong, Erroll H Rueckert are employees of NanoString Inc. All other authors declare no competing interests.
Funding Statement
This work was supported by the NIH R01CA240924 (D.T.T., B.D.G.), 7R01AI081848-04 (B.D.G.), ACD/Biotechne (N.D., A.N., A.S.K., D.T.T., M.N.R., V.D.), The MGH Research Scholars Program (M.N.R.), The Pershing Square Sohn Prize Mark Foundation Fellow (B.D.G.), the V Foundation (B.D.G., A. Solovyov), SU2C Lustgarten (D.T.T., B.D.G.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Partners Human Research IRB (Protocol #: 2020P001001)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequencing datasets generated during and/or analysed during the current study are available in the GEO repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150316. NanoString GeoMX data in process to be uploaded to NCBI.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150316
